Clinical Trials
45 trialsNCT03607539 2026-05-11
Efficacy and Safety Evaluation of Sintilimab in Patients With Advanced or Metastatic Non-squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT04877821 2026-04-02
NeoSACT
Guangdong Provincial People's Hospital
Phase 2 Completed
NCT04720716 2026-03-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT05024968 2026-02-25
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05348811 2026-01-06
HAIC Combined With Donafenib and Sintilimab for Unresectable ICC
Zhongda Hospital
Phase 2 Completed
NCT06493240 2025-11-25
NLCCRIT-LARC
Peking University People's Hospital
Phase 2 Completed
NCT05383482 2025-11-17
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
Laekna Limited
Phase 1/2 Completed
NCT07098104 2025-08-01
A Benefit Population Atlas of nICT Versus nCT for LAGC
Jiangsu Cancer Institute & Hospital
Completed
NCT04548440 2025-06-12
Efficacy and Safety of Preoperative Sintilimab Plus Nab-paclitaxel and Cisplatin in BR-ESCC Patients
Sun Yat-sen University
Phase 2 Completed
NCT03903705 2025-04-06
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors
Hutchmed
Phase 1/2 Completed
NCT03812549 2025-03-04
Safety and Tolerability Evaluation of Sintilimab in Combination With Radiation in Stage IV NSCLC Patients
Sichuan University
Phase 1 Completed
NCT04297280 2025-02-27
TACE Combined with Anti-PD-1 Antibody in Patients with Advanced Hepatocellular Carcinoma
Fudan University
Phase 2 Completed
NCT05010668 2025-02-21
Cryoablation Combined With Sintilimab Plus Lenvatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma
Fudan University
Phase 2 Completed
NCT06108596 2025-01-21
PICS
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Completed
NCT04212598 2024-12-10
The Value of Sintilimab Consolidation Therapy After Definitive Concurrent Chemoradiotherapy for Locally Advanced Thoracic Esophageal Cancer
Wuhan University
Phase 2 Completed
NCT03985046 2024-11-07
Sintilimab Plus Chemotherapy Followed by dCRT in Locally Advanced ESCC
Fudan University
Phase 2 Completed
NCT04954794 2024-10-31
TACE Combined with Sintilimab Plus Bevacizumab Biosimilar in Patients with Advanced Hepatocellular Carcinoma (TASK-02)
Fudan University
Phase 2 Completed
NCT04167657 2024-09-19
STAR
Peking Union Medical College Hospital
Phase 2 Completed
NCT03989336 2024-07-15
A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer
Chinese PLA General Hospital
Phase 2 Completed
NCT04842565 2024-05-22
cTACE Plus Sintilimab for Unresectable Intermediate-stage HCC With Beyond Up-to-seven Criteria
Fudan University
Phase 2 Completed
NCT04271813 2024-04-23
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CRC)
Shanghai Changzheng Hospital
Phase 2 Completed
NCT04618367 2024-03-06
HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT
Sun Yat-sen University
Phase NA Completed
NCT04627012 2024-03-06
Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
Sun Yat-sen University
Completed
NCT04590599 2023-12-18
A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Completed
NCT03802240 2023-11-27
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03748134 2023-10-24
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT04790409 2023-09-14
Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations
Zhejiang Cancer Hospital
Phase 2 Completed
NCT06015035 2023-08-29
Sintilimab and Anlotinib Combined With Chemotherapy in Neoadjuvant Treatment of Resectable Esophageal Cancer
Tang-Du Hospital
Phase 2 Completed
NCT05119998 2023-08-18
A Phase I Study of IBI325 in Patients With Advanced Solid Tumor
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT05026593 2023-07-19
A Study of IBI110 in Combination With Sintilimab and Chemotherapy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04055792 2023-06-28
Sintilimab Combined With Anlotinib as Second or Further-line Therapy for ED-SCLC
Henan Cancer Hospital
Phase 2 Completed
NCT04672356 2023-06-22
A Study to Evaluate the Safety , Tolerability and Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced Lung Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT04672369 2023-06-22
A Study to Evaluate the Efficacy of IBI939 in Combination With Sintilimab in Patients With Advanced NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT05809336 2023-04-12
Gut Microbial Metabolites Inosine Combined With PD-1/PD-L1 Inhibitor for Patients With Malignant Advanced Solid Tumors
Beijing Friendship Hospital
Phase 2/3 Completed
NCT03732664 2023-03-24
ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Completed
NCT03745170 2023-03-01
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03150875 2023-02-28
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT03545971 2023-02-28
A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03629925 2023-02-28
Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT04177290 2023-02-27
A PK Similarity Study of Two Sintilimab Products Produced by Different Processes in Advanced or Metastatic NSCLC Patients
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT05118334 2023-02-23
IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03758001 2023-02-22
First in Human Study of IBI101 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT02937116 2022-10-14
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03568539 2021-06-01
IBI308 in Subjects With Advanced/Metastatic Solid Malignancies
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1 Completed
NCT03116152 2021-02-03
Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Completed